The Clinical Value of Systemic Immune Inflammation Index (SII) in Predicting the Severity of Hospitalized Children with Mycoplasma Pneumoniae Pneumonia: A Retrospective Study

Shuye Wang,Yu Wan,Wenbo Zhang
DOI: https://doi.org/10.2147/ijgm.s451466
IF: 2.145
2024-03-12
International Journal of General Medicine
Abstract:Shuye Wang, 1, 2 Yu Wan, 2 Wenbo Zhang 2 1 Bengbu Medical University, Bengbu, 233000, People's Republic of China; 2 Department of Pediatrics, Changzhou No.2 People's Hospital, the Affiliated Hospital of Nanjing Medical University, Changzhou, 213000, People's Republic of China Correspondence: Wenbo Zhang, Email Objective: The Systemic Immune Inflammation Index (SII), as a novel inflammation biomarker that comprehensively reflects the inflammatory and immune status of the body, has not been reported in studies on Mycoplasma pneumoniae pneumonia (MPP) in children. This study aims to investigate whether SII can serve as an effective indicator for evaluating the condition of MPP. Methods: This study recruited a total of 304 hospitalized patients with mycoplasma pneumoniae pneumonia (MPP), including 78 patients with severe MPP (SMPP) and 226 patients with non-SMPP. Univariate analysis using chi-square test, t -test, and Mann–Whitney U -test was conducted to analyze the clinical data of the patients. Logistic regression analysis was employed to identify the main risk factors for SMPP. Receiver operating characteristic curves were plotted to evaluate the potential of using neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic immune response index (SIRI) to predict the severity of MPP. Results: The ROC curve results show that patients with SII values ≥ 699.00 are more likely to develop severe MPP (sensitivity=0.876, specificity=0.987, AUC=0.940), and the predictive value of SII is significantly better than that of NLR, PLR, and SIRI. The results of multivariate logistic regression analysis indicate that SII can serve as a major risk factor for distinguishing non-SMPP from SMPP. Conclusion: This study suggests that SII may be an effective indicator for predicting the severity of MPP in children. SII is more sensitive and specific than NLR, PLR, and SIRI in evaluating the condition of MPP. Keywords: systemic immune-inflammation index, mycoplasma pneumoniae pneumonia, severity, predictive value Mycoplasma pneumoniae pneumonia is an acute infectious disease, accounting for 10–40% of children and adolescents' community acquired pneumonia, and the incidence rate is increasing year by year. 1,2 Scholars have confirmed that compared with non-SMPP, SMPP is more likely to induce multiple system injuries in and out of the lungs, such as bronchiectasis, pulmonary embolism, obliterative bronchiolitis, encephalitis, myocarditis, hemophagocytic syndrome, etc, 3 seriously endangering the health of children. Multiple studies have shown that cellular immune mediated inflammatory responses play an important role in the occurrence and development of SMPP, and the balance between anti-inflammatory and pro-inflammatory systems directly affects the changes in the condition and clinical outcomes of pneumonia patients. 4,5 Therefore, evaluating the inflammatory status caused by MP infection can help predict the occurrence of SMPP. White blood cells are an important component of the body's response to immune inflammation. Among them, neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have been confirmed to have the potential to predict early treatment response and prognosis in CAP patients. 6–8 Systemic immune inflammation Index (SII) is a new indicator that reflects inflammation and immune balance in the body, obtained by integrating neutrophil count, lymphocyte count, and platelet count. Compared with NLR and PLR, SII can better reflect the level of inflammation. 9,10 SII has been proved to be related to the severity and prognosis of malignant tumors and many inflammatory diseases such as sepsis, COVID-19, etc. 11,12 However, there are currently no reports on the potential of SII in MPP disease assessment both domestically and internationally. The study retrospectively studied 304 children with MPP who were hospitalized in the Pediatrics Department of Changzhou Second People's Hospital affiliated with Nanjing Medical University from July 2022 to July 2023. According to the severity of the patient's condition, they are divided into the SMPP group (n=78) and the non SMPP group (n=226). Inclusion criteria: (1) Meets the diagnostic criteria in the "Guidelines for the Diagnosis and Treatment of Mycoplasma Pneumonia in Children (2023 Edition)"; 13 (2) 1–14 years old. (3) Criteria for the diagnosis of SMPP: The definition of SMPP refers to the Guidelines for the 'Diagnosis and Treatment of Mycoplasma Pneumoniae Pneumonia in Children (2023 Edition)'. 13 Exclusion criteria: (1) Patients with congenital heart disease -Abstract Truncated-
medicine, general & internal
What problem does this paper attempt to address?